Full Breakdown
Advertising Standards Authority Bans Misleading Health Supplement Ads Targeting Women's Health
3/26/2026, 12:58:33 PM
Overview of the Advertising Ban
The Advertising Standards Authority (ASA) has banned five advertisements for health supplements that made unsubstantiated claims about treating menopause symptoms and other women's hormonal conditions. The brands affected include 222 Balance Me, Lunera, Minerva, and Nova Menopause Vitality, all of which claimed their products could prevent, treat, or cure menopause-related issues. Additionally, an advertisement for PolyBiotics suggested its supplements could prevent or treat polycystic ovary syndrome (PCOS).
AI-Powered Scrutiny of Health Claims
The ASA's decision followed an AI-driven examination of health claims in online advertisements, which revealed significant issues with misleading assertions. The authority emphasized that many of the claims made in these ads were "unacceptable" and risked misleading vulnerable individuals or diverting them from appropriate medical advice. ASA investigations manager Catherine Drewett stated, "When it comes to women's health, people deserve clear and accurate information."
Responses from Advertisers
The companies involved have responded to the ASA's findings. 222 Collective, the company behind 222 Balance Me, acknowledged that its advertisements may have "inadvertently implied" that their products could treat or relieve symptoms such as PMS and menopause-related issues. They indicated that they are a new, founder-run business still learning about advertising regulations and are collaborating with Trading Standards to ensure compliance.
Lunera accepted that its claims could be interpreted as attributing medicinal properties to its food supplements, which should not have been the case. PolyBiotics conceded that references to PCOS and related symptoms constituted claims of disease treatment, which are prohibited for food supplements. In contrast, Minerva and Nova did not respond to the ASA's inquiries.
Implications of the Rulings
The ASA's actions highlight the growing concern over misleading health claims in advertisements, particularly those targeting women's health issues. The authority's commitment to monitoring this sector closely aims to protect consumers from potentially harmful misinformation. Drewett reiterated the importance of accountability in advertising, stating, "Ads making misleading claims about treating symptoms of the menopause, PCOS, and other hormonal conditions can cause real harm."
Conclusion
The ASA's ban on these advertisements underscores the need for clear and accurate information in health-related marketing. As the conversation around women's health continues to gain prominence, the authority's vigilance in regulating misleading claims is crucial to safeguarding public health. The ASA encourages anyone with concerns about misleading advertisements to come forward.
